U.S. Capital Wealth Advisors’s Xylem XYL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$211K Sell
1,764
-7,484
-81% -$981K 0.01% 941
2025
Q4
$1.26M Buy
+9,248
New +$1.33M 0.03% 435
2025
Q2
Sell
-8,153
Closed -$974K 937
2025
Q1
$974K Buy
8,153
+285
+4% +$35.3K 0.03% 428
2024
Q4
$913K Buy
7,868
+98
+1% +$12.4K 0.03% 441
2024
Q3
$1.05M Sell
7,770
-145
-2% -$19.4K 0.04% 347
2024
Q2
$1.07M Buy
7,915
+5
+0.1% +$680 0.04% 335
2024
Q1
$1.02M Sell
7,910
-8
-0.1% -$967 0.04% 342
2023
Q4
$906K Sell
7,918
-438
-5% -$43.7K 0.04% 346
2023
Q3
$761K Hold
8,356
0.03% 352
2023
Q2
$941K Buy
8,356
+756
+10% +$80K 0.04% 337
2023
Q1
$796K Buy
7,600
+100
+1% +$10.4K 0.04% 344
2022
Q4
$829K Hold
7,500
0.04% 364
2022
Q3
$655K Buy
7,500
+198
+3% +$18K 0.03% 400
2022
Q2
$571K Sell
7,302
-2,400
-25% -$198K 0.03% 435
2022
Q1
$827K Hold
9,702
0.03% 426
2021
Q4
$1.16M Hold
9,702
0.05% 370
2021
Q3
$1.2M Buy
+9,702
New +$1.25M 0.05% 352

Other funds holding XYL

U.S. Capital Wealth Advisors's XYL Position: Q1 2026 in Review

U.S. Capital Wealth Advisors reduced its Xylem (XYL) stake by 81% in Q1 2026, selling an estimated $981K and leaving 1,764 shares worth $211K. The position accounts for 0.01% of the portfolio, ranked #941.

U.S. Capital Wealth Advisors first reported a position in XYL in Q3 2021 and has held it in 17 quarters since. The position peaked at $1.26M in Q4 2025. 1,107 funds tracked by Wall St. Rank hold XYL as of Q1 2026.

  • U.S. Capital Wealth Advisors held 1,764 shares of Xylem worth $211K as of Q1 2026.
  • U.S. Capital Wealth Advisors sold 7,484 Xylem shares in Q1 2026, an estimated $981K.
  • Xylem made up 0.01% of U.S. Capital Wealth Advisors's portfolio in Q1 2026, its #941 holding.
  • U.S. Capital Wealth Advisors first reported a position in Xylem in Q3 2021 and has held it in 17 quarters since.
  • U.S. Capital Wealth Advisors's Xylem position peaked at $1.26M in Q4 2025.
  • 1,107 funds tracked by Wall St. Rank held Xylem as of Q1 2026.

Based on U.S. Capital Wealth Advisors's 13F filing for Q1 2026, filed 7 Apr 2026.